At CD BioSciences, we specialize in providing highly customized research project solutions for clients seeking advanced, preclinical-stage support in the field of human herpesvirus (HHV). With our deep expertise across HHV biology, antiviral strategies, gene therapy, diagnostics, and oncolytic virotherapy, we empower pharmaceutical companies, biotechnology firms, and academic institutions with bespoke research capabilities tailored to their unique project goals.
Whether you require a fully integrated preclinical package or modular assistance in target validation, assay development, or vector construction, our dedicated scientific team works closely with you to co-design and execute HHV-related studies that accelerate discovery and de-risk development.
Why Choose CD BioSciences for Custom HHV Research Projects?
CD BioSciences is exclusively focused on HHV-related research, making us a strategic partner for clients tackling complex herpesvirus-driven diseases such as Kaposi's sarcoma (HHV-8), primary effusion lymphoma, CMV-related conditions, and herpes simplex virus (HSV) infections. Our custom project services combine:
In-depth HHV knowledge base across all known human herpesviruses (HHV-1 to HHV-8).
Cutting-edge laboratory infrastructure supporting molecular, cellular, immunological, and in vivo capabilities.
Flexible engagement models, including full-scope, milestone-based, or collaborative service agreements.
Compliance with preclinical development standards, including GLP-aligned reporting and IND-enabling data packages.
Our Custom Solutions Cover the Following Domains
- Antiviral Drug Discovery Support
We assist clients in discovering and characterizing new antiviral agents targeting HHV replication, latency, and immune evasion mechanisms.
Customizable Modules Include:
Target Identification & Validation
Using genetic screens, omics-based profiling, and CRISPR editing in HHV-infected models.
Hit-to-Lead Development
Small molecule screening in primary cell or immortalized infection systems; cytotoxicity profiling.
Preclinical Candidate Nomination
In vitro and in vivo efficacy studies, ADMET profiling, and mechanism-of-action elucidation.
Latency-targeted Strategies
Re-activation assays, latency reversal agents (LRAs), and epigenetic modulator testing.
Our antiviral team designs studies that consider strain diversity, host range, and resistance potential—critical for herpesvirus drug development.
- Vaccine Development and Evaluation
We offer comprehensive project support for HHV vaccine candidates, from antigen design to immune profiling in vivo.
Available Services:
Antigen Discovery & Design
Epitope mapping, glycoprotein modeling, and expression in various vector formats (mRNA, DNA, viral).
Vaccine Candidate Construction
Plasmid DNA, viral vectors (e.g., AAV, adenovirus), or protein subunit platforms.
Adjuvant & Formulation Screening
Screening libraries of adjuvants for immune potentiation and delivery optimization.
Preclinical Immunogenicity Packages
Antibody titers (ELISA, neutralization assays), T-cell assays (ICS, ELISpot), challenge models in vivo.
We tailor the workflow based on the intended immune response (Th1/Th2 balance, mucosal vs. systemic) and virus-specific challenges.
- Diagnostic Development Services
Our diagnostics division supports HHV-related assay development with clinical relevance and translational potential.
Customizable Offerings:
Biomarker Discovery & Validation
Transcriptomics, proteomics, and metabolomics approaches in HHV-infected cells or patient samples.
Assay Development Support
Design and optimization of qPCR, LAMP, ELISA, multiplex immunoassays, and biosensor platforms.
We help clients develop sensitive and specific diagnostic tools for disease detection, prognosis, or treatment monitoring—especially critical for latent or chronic herpesvirus infections.
- Gene Therapy Development Solutions
Leveraging viral vectors and genome engineering tools, we support custom gene therapy projects focused on targeting or utilizing HHVs.
Capabilities Include:
Vector Construction
AAV, lentivirus, and HSV-based constructs; packaging, titration, and QC.
In Vivo Delivery Optimization
Tissue-targeted delivery strategies, biodistribution studies, and safety assessment.
Expression Verification
qPCR, Western blot, and immunostaining in relevant in vitro and in vivo models.
Our experience with HSV as both a vector and a target pathogen provides clients with unique dual-perspective insights.
- Oncolytic Herpes Simplex Virus (oHSV) Therapy Projects
CD BioSciences provides end-to-end support for projects involving engineered oHSVs for cancer immunotherapy.
Customizable Services:
oHSV Engineering & Validation
Genetic manipulation of HSV backbone, transgene insertion, safety engineering (ICP34.5, γ34.5 deletions).
Oncolytic Activity Assessment
In vitro cytolytic assays, 3D tumor spheroids, and xenograft models.
Immune Profiling & Combination Therapy Evaluation
Flow cytometry, cytokine analysis, checkpoint inhibitor synergy testing.
Biodistribution & Viral Shedding Studies
Tissue tropism, viral kinetics, and host clearance mechanisms in murine or humanized models.
These services help biotech and pharma clients advance next-generation oHSV-based immunotherapies efficiently and safely.
How We Collaborate
At CD BioSciences, we understand that every HHV-focused research project is different. Our engagement process includes:
Project
Scoping Call
Understanding your objectives, timelines, and regulatory context.
Proposal
Development
Modular service menu with transparent milestones and deliverables.
Execution
& Reporting
Weekly updates, interim data reviews, and final reporting packages suitable for regulatory submission or investor presentation.
Scientific
Partnership
Weekly updates, interim data reviews, and final reporting packages suitable for regulatory submission or investor presentation.
Our Commitment to Scientific Excellence
All of our custom services are delivered by a multidisciplinary team of virologists, immunologists, molecular biologists, and translational scientists. We maintain rigorous internal standards and leverage validated HHV models, reference strains, and quality-controlled reagents.
If you're developing novel therapeutics, diagnostics, or gene therapies against HHVs, CD BioSciences is ready to support you with agile, expert-driven custom research services. Contact us to schedule a consultation and let's design a solution tailored to your success.
References
- Whitley, R. J., & Roizman, B. (2001). Herpes simplex viruses. Clin Infect Dis, 26(3), 541–553.
- Mocarski, E. S., et al. (2021). Cytomegaloviruses. In Fields Virology (7th ed.).
- Knipe, D. M., & Cliffe, A. (2008). Chromatin control of herpes simplex virus lytic and latent infection. Nat Rev Microbiol, 6(3), 211–221.
- Liu, T. C., & Kirn, D. (2007). Gene therapy progress and prospects: oncolytic viruses. Gene Ther, 14(5), 349–356.
- Pellett, P. E., & Roizman, B. (2013). The Family Herpesviridae: A Brief Introduction. In Fields Virology (6th ed.).